Translational Medicine in CNS Drug Development

Volume 29
Herausgeber: Nomikos, George G; Feltner, Douglas E

• Gebundenes Buch

Produktbeschreibung

Translational Medicine in CNS Drug Development, Volume 29, is the first book of its kind to offer a comprehensive overview of the latest developments in translational medicine and biomarker techniques. With extensive coverage on all aspects of biomarkers and personalized medicine, and numerous chapters devoted to the best strategies for developing drugs that target specific disorders, this book presents an essential reference for researchers in neuroscience and pharmacology who need the most up-to-date techniques for the successful development of drugs to treat central nervous system disorders. Despite increases in the number of individuals suffering from CNS-related disorders, the development and approval of drugs for their treatment have been hampered by inefficiencies in advancing compounds from preclinical discovery to the clinic. However, in the past decades, game-changing strides have been made in our understanding of the pathophysiology of CNS disorders and the relationship of drug exposure in plasma and CNS to pharmacodynamic measures in both animals and humans.

Produktdetails

• Verlag: Elsevier Health Sciences
• Seitenzahl: 458
• Erscheinungstermin: 3. Juli 2019
• Englisch
• Abmessung: 282mm x 218mm x 25mm
• Gewicht: 1497g
• ISBN-13: 9780128031612
• ISBN-10: 0128031611
• Artikelnr.: 51250176

Inhaltsangabe

1. Translating animal models of obesity and diabetes to the clinic 2.
Biomarker-guided drug development for better defined early patient studies
and clinical trial efficiency 3. Modeling and simulation in the
translational pharmacology of cns drugs 4. Functional measurements of
central nervous system drug effects in early human drug development 5.
Experimental medicine approaches in cns drug development 6. New approaches
in translational medicine for phase i clinical trials of cns drugs 7.
Translational approaches for antidepressant drug development 8. Biomarker
opportunities to enrich clinical trial populations for drug development in
schizophrenia and depression 9. Applications of neuroimaging biomarkers in
cns drug development 10. Pet occupancy and competition in translational
medicine and cns drug development 11. Stable isotope labeling kinetics in
cns translational medicine: introduction to silk technology 12.
Applications of neurophysiological biomarkers in cns drug development:
focus on psychoses 13. Heart rate variability as a translational biomarker
for emotional and cognitive deficits 14. Drug discovery in psychiatry: time
for human genome-guided solutions 15. Use of cognition to guide decisions
about the safety and efficacy of drugs in early-phase clinical trials 16.
Digital biomarkers in clinical drug development 17. Lessons learned from
public private partnerships and consortia: the adni paradigm 18. Regulatory
perspectives on the use of biomarkers and personalized medicine in cns drug
development: the fda viewpoint 19. Regulatory considerations for the use of
biomarkers and personalized medicine in cns drug development: a european
perspective 20. Regulatory science objectives and biomarker qualification
through public-private partnerships are critical to delivering innovative
treatments for cns diseases 21. The assessment of cognition in
translational medicine: a contrast between the approaches used in
alzheimer's disease and major depressive disorder 22. Translational
medicine strategies in drug development for neurodevelopmental disorders
23. Translational medicine strategies in drug development for mood
disorders 24. Translational medicine strategies in alzheimer's disease drug
development 25. Experimental medicine models in generalized anxiety
disorder and social anxiety disorder 26. Translational medicine strategies
in ptsd drug development 27. Unmet medical needs in the treatment of
depression and the clinical development of a differentiated antidepressant:
a translational line of evidence 28. Translating neurobiology into practice
in tobacco, alcohol, drug, and behavioral addictions 29. Translational
medicine strategies for drug development for impulsive aggression 30.
Hypothesizing major depression as a subset of reward deficiency syndrome
(rds) linked to polymorphic reward genes: considerations for translational
medicine approaches for future drug development 31. Traveling through the
storm: leveraging virtual patient monitoring and artificial intelligence to
observe, predict, and affect patient behavior in cns drug development